Last reviewed · How we verify

Mansoura Integrated Fertility Center — Portfolio Competitive Intelligence Brief

Mansoura Integrated Fertility Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Progesterone 100 IM/day Progesterone 100 IM/day marketed Progestin; steroid hormone Progesterone receptor (PR) Reproductive/Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Mansoura Integrated Fertility Center:

Cite this brief

Drug Landscape (2026). Mansoura Integrated Fertility Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mansoura-integrated-fertility-center. Accessed 2026-05-17.

Related